+

WO2007015270A3 - Novel controlled release compositions of selective serotonin reuptake inhibitors - Google Patents

Novel controlled release compositions of selective serotonin reuptake inhibitors Download PDF

Info

Publication number
WO2007015270A3
WO2007015270A3 PCT/IN2006/000274 IN2006000274W WO2007015270A3 WO 2007015270 A3 WO2007015270 A3 WO 2007015270A3 IN 2006000274 W IN2006000274 W IN 2006000274W WO 2007015270 A3 WO2007015270 A3 WO 2007015270A3
Authority
WO
WIPO (PCT)
Prior art keywords
controlled release
composition
active
serotonin reuptake
released
Prior art date
Application number
PCT/IN2006/000274
Other languages
French (fr)
Other versions
WO2007015270A2 (en
Inventor
Avinash K Velhal
Vineeth Raghavan
Suryakumar Jayanthi
Himadri Sen
Original Assignee
Lupin Ltd
Avinash K Velhal
Vineeth Raghavan
Suryakumar Jayanthi
Himadri Sen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd, Avinash K Velhal, Vineeth Raghavan, Suryakumar Jayanthi, Himadri Sen filed Critical Lupin Ltd
Priority to AU2006274565A priority Critical patent/AU2006274565B2/en
Priority to JP2008524679A priority patent/JP5153629B2/en
Publication of WO2007015270A2 publication Critical patent/WO2007015270A2/en
Publication of WO2007015270A3 publication Critical patent/WO2007015270A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A controlled release pharmaceutical composition of a selective serotonin reuptake inhibitor. The composition essentially comprises of a core comprising the active ingredient, one or more controlled release polymer(s) and one or more pharmaceutically acceptable excipients. The composition optionally will have a coating comprising one or more controlled release polymers. The composition is prepared by mixing the active ingredient with one or more controlled release polymers and one or more pharmaceutically acceptable excipients. Thereafter the mixture is granulated, dried, lubricated and compressed into tablets. The composition is used in the manufacture of a medicament, for treating and/or preventing the disorders. The active is released between about 2-8 hours with about 10-25% of active is released in vitro in 2 hours in 0.1N HCl, 750 ml dissolution medium using USP Dissolution tester, paddle method at 150 rpm. About 20-55%, 50-75% and 70-95% of active is released in vitro in 4,6 and 8 hours respectively in pH 7.5 Tris buffer, 1000 ml dissolution medium using USP Dissolution tester, paddle method at 150 rpm.
PCT/IN2006/000274 2005-08-02 2006-08-01 Novel controlled release compositions of selective serotonin reuptake inhibitors WO2007015270A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2006274565A AU2006274565B2 (en) 2005-08-02 2006-08-01 Novel controlled release compositions of selective serotonin reuptake inhibitors
JP2008524679A JP5153629B2 (en) 2005-08-02 2006-08-01 Novel controlled release compositions of selective serotonin reuptake inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN696KO2005 2005-08-02
IN696/KOL/2005 2005-08-02

Publications (2)

Publication Number Publication Date
WO2007015270A2 WO2007015270A2 (en) 2007-02-08
WO2007015270A3 true WO2007015270A3 (en) 2007-04-19

Family

ID=37392535

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000274 WO2007015270A2 (en) 2005-08-02 2006-08-01 Novel controlled release compositions of selective serotonin reuptake inhibitors

Country Status (3)

Country Link
JP (1) JP5153629B2 (en)
AU (1) AU2006274565B2 (en)
WO (1) WO2007015270A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010002692A (en) 2007-09-13 2010-06-01 Concert Pharmaceuticals Inc Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof.
DK2470166T3 (en) * 2009-08-24 2013-09-08 Lundbeck & Co As H NEW COMPOSITIONS OF 1- [2- (2,4-DIMETHYL-PHENYLSULPHANYL) -PHENYL] PIPERAZINE
KR20140045925A (en) 2011-03-17 2014-04-17 루핀 리미티드 Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
KR102441089B1 (en) * 2020-06-15 2022-09-07 환인제약 주식회사 A Pharmaceutical Composition
CN112494445A (en) * 2020-12-11 2021-03-16 丽珠集团丽珠制药厂 Fluvoxamine maleate composition and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003670A1 (en) * 1995-07-20 1997-02-06 Smithkline Beecham P.L.C. Paroxetine controlled release compositions
WO1999000131A1 (en) * 1997-06-30 1999-01-07 Endo Pharmaceuticals Inc. Novel process for manufacturing paroxetine solid dispersions
WO1999056751A1 (en) * 1998-05-07 1999-11-11 Endo Pharmaceuticals Inc. Aqueous process for manufacturing paroxetine solid dispersions
WO2002069969A1 (en) * 2001-03-02 2002-09-12 A/S Gea Farmaceutisk Fabrik A process for the manufacture of pharmaceutical tablets containing paroxetine hydrochloride anhydrate
WO2004058229A1 (en) * 2002-12-24 2004-07-15 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
EP1027888B1 (en) * 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
PT1178780E (en) * 1999-05-20 2007-10-25 Elan Pharma Int Ltd Multiparticulate controlled release selective serotonin reuptake inhibitor formulations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003670A1 (en) * 1995-07-20 1997-02-06 Smithkline Beecham P.L.C. Paroxetine controlled release compositions
WO1999000131A1 (en) * 1997-06-30 1999-01-07 Endo Pharmaceuticals Inc. Novel process for manufacturing paroxetine solid dispersions
WO1999056751A1 (en) * 1998-05-07 1999-11-11 Endo Pharmaceuticals Inc. Aqueous process for manufacturing paroxetine solid dispersions
WO2002069969A1 (en) * 2001-03-02 2002-09-12 A/S Gea Farmaceutisk Fabrik A process for the manufacture of pharmaceutical tablets containing paroxetine hydrochloride anhydrate
WO2004058229A1 (en) * 2002-12-24 2004-07-15 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DOUGHTY D G ET AL: "Dry Formulation Process Improves Stability of Paroxetine Tablets - Useful in the Treatment of Depression, Neuroses, Etc", STN WPIDS, 22 June 1995 (1995-06-22), XP002913188 *

Also Published As

Publication number Publication date
JP5153629B2 (en) 2013-02-27
AU2006274565B2 (en) 2012-05-17
AU2006274565A1 (en) 2007-02-08
JP2009503057A (en) 2009-01-29
WO2007015270A2 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
WO2003072025A3 (en) Modified release formulations of at least one form of tramadol
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
WO2001078725A3 (en) Modified release formulations containing a hypnotic agent
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
RS52764B (en) Pramipexole once-daily dosage form
WO2007010559A3 (en) Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor
WO2007015270A3 (en) Novel controlled release compositions of selective serotonin reuptake inhibitors
MY148370A (en) Sustained-release composition and method for producing the same
MX2012013135A (en) Manufacturing of active-free granules and tablets comprising the same.
WO2003005967A3 (en) Dual release levodopa ethyl ester and decarboxylase in controlled release core
CA2415154A1 (en) Modified release formulations of selective serotonin re-uptake inhibitors
ATE253354T1 (en) CAPSULES WITH COMPOSITIONS CONTAINING LORATADINE AND PSEUDOEPHEDRINE
DE60035579D1 (en) MULTIPARTICELY MEDICAMENT COMPOSITIONS WITH A CONTROLLED ACTIVE INGREDIENT DELIVERING SELECTIVE INHIBITORS OF SEROTONIN RECOVERY
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
JP2004522780A5 (en)
IS6504A (en) New Galician drug release with slow release of molsidomine
US20030229101A1 (en) Tablets comprising ciprofloxacin hydrochloride
WO2002017877A3 (en) Controlled release pharmaceutical pellet compositions for reducing side effects of drugs
CA2617351A1 (en) Diltiazem controlled release formulation and method of manufacture
ATE382332T1 (en) CONTROLLED RELEASE FORMULATION CONTAINING TAMSULOSINE HYDROCHLORIDE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008524679

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006274565

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2006274565

Country of ref document: AU

Date of ref document: 20060801

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006274565

Country of ref document: AU

122 Ep: pct application non-entry in european phase

Ref document number: 06780554

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载